Premium
O4‐08‐04: Resveratrol Activates the CNS SIRTUIN1/Matrix Mettaloproteinase‐9 Pathway and Regulates Neuroinflammation in Alzheimer's Disease
Author(s) -
E-H Moussa Charbel,
Hebron Michaeline,
Huang Xu,
Brown Hannah J.,
Rissman Robert A.,
Aisen Paul S.,
Turner Raymond Scott
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.652
Subject(s) - resveratrol , neuroinflammation , adam10 , mmp9 , ccl22 , chemokine , sirtuin 1 , medicine , immunology , pharmacology , endocrinology , chemistry , cancer research , inflammation , matrix metalloproteinase , downregulation and upregulation , biochemistry , chemokine receptor , metalloproteinase , disintegrin , gene
Study Activities of Daily Living; ADCS-ADL) scores. Threemonthly assessment included magnetic resonance imaging (MRI) as a disease modifying outcome. Other secondary outcomes included ADCS-CGIC and MMSE. Results:A total of 891 patients were randomized, of whom 62% were female. Approved AD treatments were being taken in 85%. The mean age was 70.6 (SD 9.0) years and baseline MMSE score was 18.7 (SD 3.4). Dementia was of moderate severity (MMSE score 14-19) in 61%. The study efficacy and safety outcomes will be reported. Conclusions:The outcomes of this phase 3 trial will highlight the potential therapeutic value of tau aggregation inhibitor therapy in AD. A second phase 3 trial of LMTM for AD will be completed and reported later in 2016.